Innohep

Tinzaparin sodium, the active ingredient in Innohep, is a low molecular weight heparin presented as an injectable solution for subcutaneous, intravenous and haemodialysis use. It prevents and treats deep vein thrombosis, pulmonary embolism, and provides anticoagulation during haemodialysis.

GNH USA supplies Innohep as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Innohep (tinzaparin sodium) is used in the anticoagulation pathway to prevent and treat thromboembolic conditions.

- Deep vein thrombosis (DVT): prevents clot formation and facilitates clot resolution in patients at risk or with established DVT. - Pulmonary embolism (PE): reduces the risk of embolic events and supports treatment of acute PE. - Surgical thromboprophylaxis: lowers incidence of postoperative venous thromboembolism in patients undergoing major surgery. - Haemodialysis anticoagulation: provides anticoagulation during haemodialysis procedures to maintain circuit patency.

Tinzaparin sodium may be associated with a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Injection site reactions: erythema, pain, or bruising at the administration site. - Minor bleeding: epistaxis, gum bleeding, or easy bruising. - Elevated liver enzymes: transient increases in hepatic transaminases. - Nausea or abdominal discomfort: occasional gastrointestinal upset.

Serious or Rare Side Effects: - Major hemorrhage: life‑threatening bleeding such as intracranial or gastrointestinal. - Thrombocytopenia: heparin‑induced thrombocytopenia (HIT) with platelet count drop. - Allergic reactions: anaphylaxis, urticaria, or angioedema. - Spinal/epidural hematoma: bleeding in spinal canal after neuraxial procedures.

Before initiating tinzaparin therapy, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: adjust dose or monitor anti‑Xa levels in patients with severe kidney dysfunction. - Bleeding risk: evaluate history of active bleeding, recent surgery, or coagulopathy. - Concomitant anticoagulants: avoid or closely monitor use with other anticoagulants or antiplatelet agents. - Pregnancy: category B, use only if benefit outweighs potential risk to fetus. - Spinal procedures: postpone neuraxial anesthesia or puncture until anticoagulant effect has subsided. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Tinzaparin sodium can interact with other medicines, altering its anticoagulant effect or increasing bleeding risk.

Major Interactions (Avoid): - Concurrent use with warfarin or direct oral anticoagulants: markedly increased bleeding risk. - Combination with antiplatelet drugs (e.g., clopidogrel, aspirin) at full doses: synergistic anticoagulation. - Non‑steroidal anti‑inflammatory drugs (NSAIDs) or corticosteroids: heightened hemorrhagic potential.

Moderate Interactions (Monitor Closely): - Heparin flushes or low‑dose unfractionated heparin: additive anti‑Xa activity. - Thrombolytic agents (e.g., alteplase): increased risk of major bleeding. - Certain antibiotics (e.g., vancomycin) that may affect platelet function: monitor for bleeding.